Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

ABSTRACT:

Background

Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials.

Methods

We systematically reviewed randomised trials comparing treatment regimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both PFS and overall survival with a standard hazard ratio (HR). We correlated HRs for overall survival and PFS, weighted by sample size or by precision of the HR estimate, assuming fixed and random effects. We did sensitivity analyses according to presence of crossover, trial size, and dacarbazine dose.

Findings

After screening 1649 reports

SUBMITTER: Flaherty KT 

PROVIDER: S-EPMC4443445 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature